Takeda Q1 FY2027: Revenue Up 10.2% on Weak Yen, but Underlying Sales, Profit Dip

Takeda’s consolidated revenue for the April-June quarter came to ¥1,219.9 billion, up 10.2% from a year earlier, but the increase was driven almost entirely by a weaker yen. On a constant currency (CER) basis, revenue slipped 0.5%. Operating profit rose 9.1% to ¥201.4 billion, though on a CER basis it fell 3.1%. Net profit attributable to the parent company declined 8.9% to ¥113.2 billion, weighed down by an 87.7% jump in income tax expenses.

The underlying profit picture was also pressured by higher restructuring and R&D costs. Business transformation charges surged ¥35.8 billion from the prior-year quarter, and R&D spending climbed 16.3% to ¥167.4 billion as the company invested in late-stage pipeline assets. While the full-year forecast calls for a bottom-line recovery, management’s preferred Core operating profit is projected to decline 5-8% on a CER basis, suggesting a full earnings turnaround remains some way off.

Revenue by business area (actual exchange rates) and CER growth rates are shown below.

Gastrointestinal was led by the ulcerative colitis treatment Entyvio, which posted sales of ¥268.3 billion (AER +15.4%, CER +3.8%), driven by uptake of the subcutaneous formulation in the U.S. and patient growth in Europe. The short bowel syndrome therapy Gattex/Revestive also grew 19.0%.

Rare Diseases struggled with a CER decline of 5.8%. The hereditary angioedema treatment Takhzyro lost ground in the U.S. amid intensifying competition, while the hemophilia A therapy Advate fell 7.7% (AER) due to biosimilar pressure. In contrast, the post-transplant CMV infection therapy Livtencity grew 33.7% on market penetration gains.

Plasma-Derived Therapies rose 8.8% on AER but dipped 2.1% on CER. Subcutaneous immunoglobulin products Cuvitru and HyQvia delivered double-digit growth.

Oncology recorded the strongest CER growth at 8.2%, with the lymphoma treatment Adcetris up 30.3% and the colorectal cancer drug Fruzaqla surging 38.9% as new products gained traction.

Neuroscience saw the major depressive disorder treatment Trintellix rebound 31.6%, helped by the anniversary of a distribution model change, but the ADHD therapy Vyvanse fell 6.5% on generic erosion in the U.S. Overall, generic-driven revenue decline is becoming increasingly visible.

At the end of the first quarter, total assets stood at ¥15,663.3 billion, up ¥151.8 billion from the prior fiscal year-end, driven by increases in trade receivables, goodwill, and inventories, while cash and cash equivalents fell ¥134.1 billion. Total liabilities rose ¥23.5 billion to ¥8,104.4 billion. Bonds and borrowings totaled ¥4,940.0 billion (including ¥4,715.0 billion in bonds and ¥225.0 billion in borrowings), with a ¥58.1 billion increase mainly from foreign exchange translation. Total equity increased ¥128.2 billion to ¥7,558.9 billion, with the parent owners’ equity ratio at 48.3%.

Operating cash flow was ¥127.6 billion, a sharp decline of ¥87.8 billion year-on-year, primarily due to higher trade receivables. Investing cash flow was negative ¥87.7 billion, reflecting increased expenditure on intangible assets. Financing cash flow improved to negative ¥180.3 billion, as the prior year’s share buybacks and bond issuances were absent.

On shareholder returns, Takeda plans to raise its annual dividend from ¥200 to ¥204 per share. The adjusted net debt to adjusted EBITDA ratio was 2.7x, indicating maintained financial health and ample capacity for large-scale acquisitions.

Takeda left its full-year FY2026 (ending March 2027) forecasts unchanged from its May 13 announcement. The company projects revenue of ¥4,640.0 billion (up 3.0%), operating profit of ¥420.0 billion (compared with ¥6.2 billion last year), and net profit attributable to owners of ¥166.0 billion (versus a ¥152.4 billion loss). The sharp swings mainly reflect the absence of the ¥403.5 billion antitrust litigation provision related to AMITIZA booked in the prior year.

However, management’s focus metrics point to lower underlying profitability: Core operating profit is forecast at ¥1,160.0 billion (down 1.1%), and Core EPS at ¥472 (down 8.7%). On a CER basis, Core revenue is guided to a low-single-digit decline, Core operating profit to a 5-8% decline, and Core EPS to a mid-teens decline.

Capital expenditure (cash-flow basis) is planned at ¥330.0-380.0 billion, down from ¥410.9 billion last year. R&D expenses are projected to climb 12.7% to ¥762.0 billion, driven by advancing late-stage pipeline assets.

Key risks facing Takeda include:

• Generic erosion: Loss of exclusivity on products such as Vyvanse is intensifying generic competition, particularly in the U.S., contributing to CER-based revenue declines.
• Currency volatility: Performance is highly sensitive to exchange rates, with a strengthening yen posing downside risk, especially versus the dollar and euro.
• Competitive pressure: In Rare Diseases, Takhzyro and Advate face aggressive competitors, making market share defense a challenge.
• Litigation and regulatory risk: As demonstrated by the AMITIZA settlement, pharmaceutical firms face ongoing litigation risk; provisions for legal matters are expected again this year.
• R&D uncertainty: Increased late-stage pipeline investment does not guarantee approval or commercial success, and rising R&D costs could compress profits.
• Transformation program execution: While cost savings from restructuring are anticipated, near-term restructuring charges may delay profit improvement.

Takeda invested ¥167.4 billion in R&D during the quarter, a 16.3% year-on-year increase (CER +6.8%), underscoring ongoing investment. The rise was driven largely by spending on late-stage pipeline programs such as elritercept, TAK-928, and TAK-921, which are viewed as future growth drivers.

Capital expenditure on a cash-flow basis reached ¥103.2 billion, up 37.5%, with a notable increase in acquisitions of intangible assets, reflecting aggressive in-licensing and technology deals. The company remains committed to growth investment, with full-year capex budgeted at ¥330.0-380.0 billion.